Microfluidic organoid-slice-on-a-chip system for studying anti-cholangiocarcinoma drug efficacy and hepatorenal toxicity
Jie Liu, Guohua Wu, Di Wu, Lin Wu, Chenwei Sun, Wenlong Zhang, Qijun Du, Qinrui Lu, Wenqi Hu, Hongyu Meng, Luo Zhi, Guangzhi Liu, Bangchuan Hu, Hai‐Jie Hu, Shuqi Wang
Abstract
due to patient variability. Post-treatment, RLS and RKS cell viability remained high at 75.67% and 81.03%, respectively, suggesting low hepatorenal toxicity of T-DM1 for treating cholangiocarcinoma. Our study demonstrates the use of an organoid-slice-on-a-chip (OSOC) platform for personalized drug efficacy and toxicity assessment, particularly aiming at leveraging anticancer drugs for off-label use to save patient lives.
Topics & Concepts
Organ-on-a-chipOrganoidDrug toxicityDrugMicrofluidic chipDrug developmentChipToxicityMicrofluidicsNanotechnologyPharmacologyComputer scienceMedicineBiologyInternal medicineMaterials scienceCell biologyTelecommunications3D Printing in Biomedical ResearchInnovative Microfluidic and Catalytic Techniques Innovation